Bicycle Therapeutics PLC BCYC
Bicycle Therapeutics PLC (Nasdaq: BCYC) is an oncology drug developer. Its lead program, nuzefatide pevedotin (formerly BT5528), is in Phase 2 for advanced solid tumors / recurrent metastatic pancreatic ductal adenocarcinoma. Its next catalyst on record is BT1702: IND-enabling activities underway (date not stated).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: BT1702 — IND-enabling activities underway (date not stated). 1 catalyst on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| nuzefatide pevedotin (EphA2 BDC) | advanced solid tumors / recurrent metastatic pancreatic ductal adenocarcinoma | small molecule | Phase 2 |
| zelenectide pevedotin (Nectin-4 BDC) | metastatic urothelial cancer | small molecule | Phase 2 |
| BT7480 (Nectin-4 / CD137 Bicycle TICA) | advanced solid tumors | biologic-other | Phase 1 |
| BT1702 (MT1-MMP BRC) | oncology (specific indication not stated) | radiopharmaceutical | Pre-clinical |
Recent results and decisions
- May 21, 2026positive Optimal-dose combination showed 65% (17/26) ORR and 58% (15/26) BICR-confirmed ORR at week 27, with low skin reaction (17%) and neuropathy (33%) rates; median PFS immature.
65% (17/26) overall response rate (ORR) regardless of confirmation and blinded independent central review (BICR) confirmed ORR of 58% (15/26) at the 27-week cutoff.
Filing - Mar 17, 2026positive Duravelo-2 dose selection identified 6mg/m2 as optimal with physician-assessed ORR 65% and BICR-confirmed ORR 58% at 27 weeks, comparable to standard of care.
Initial dose selection data from the Duravelo-2 trial demonstrate response rates comparable to those published for existing standards of care, with physician assessed overall response rate (ORR) of 65%, blinded independent central review (BICR) confirmed ORR of 58% at the 27-week cutoff and a differ
Filing - Mar 17, 2026started Phase 2 trial of nuzefatide in recurrent PDAC began enrolling in March 2026.
In March 2026, Bicycle Therapeutics began enrolling a Phase 2 clinical trial to evaluate efficacy, safety, and pharmacokinetics of nuzefatide in adult patients with recurrent pancreatic ductal adenocarcinoma (PDAC).
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 oncology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.